AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 281 min read$FLGT

Gao Hanlin sold $19K of FLGT

Gao Hanlin (Chief Scientific Officer) sold 939 shares of Fulgent Genetics, Inc. (FLGT) at $19.91 on 2026-08-27.

Original reporting
SEC EDGAR · Gao Hanlin
Published Aug 28, 2026, 10:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 10:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$FLGT
Neutral
high confidence
Mentioned
$FLGT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FLGTNeutralLow
01

Why it matters

Limited impact; market likely to ignore due to small size.

02

Market read

Routine insider sale with minimal market relevance.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 3/10Novelty 4/10Timing: filed today

Background

Form 4 filing discloses insider transactions; standard regulatory disclosure.

Company-level read

Ticker impact

$FLGTNeutralHigh confidence
Context

Chief Scientific Officer sold 939 shares for $18,691, reducing his stake to 987,790 shares.

Expected impact

No significant price impact expected.

Evidence & confidence

The sale amount is small relative to total holdings and market cap.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

Insider sale could signal concerns, but size is trivial.

Key entities

  • Officer
    Gao Hanlin

    Chief Scientific Officer of Fulgent Genetics, Inc.

  • Company
    Fulgent Genetics, Inc.

    Biotech firm listed on NASDAQ under ticker FLGT.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

FLGT insider trading history →

Related articles

AUG 8
$FLGTMedAI 8/10

Fulgent Genetics (FLGT) Q2 2026 Earnings Call Transcript

Fulgent Genetics (FLGT) reported Q2 2026 revenue of $85.4M, up 4% year over year and 20% sequentially, driven by Bako Diagnostics and StrataDX integration. Non-GAAP gross margin was 31.3% and Adjusted EBITDA was a $17.1M loss. Full-year revenue guidance was cut to $330M-$340M due to lower collection rates from a billing system transition.

fool.com7 min
JUL 30
$FLGTMed

Fulgent Reports Second Quarter 2026 Financial Results

Fulgent Genetics, Inc. (FLGT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Fulgent Reports Second Quarter 2026 Financial Results • Revenue of $85.4 million, growing 20.1% sequentially • GAAP gross profit of $25.7 million, or GAAP gross margin of 30.1%; Non-GAAP gross profit of $26.8 million, or Non-GAAP gross margin of 31.3% • GAAP loss of

SEC EDGAR 8-K6 min